Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Exclusion Criteria

• •Previous radiation therapy to the pelvis.
• •Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer.
• •Use of 5-alpha reductase inhibitor within the 3 months prior to dosing.
• •Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging.
• •Inability to tolerate transrectal ultrasound (TRUS).
• •Known allergy to latex or gadolinium (Gd).
• •Prior rectal surgery preventing insertion of the TRUS probe.
• •Any previous ablative procedures performed on the prostate, e.g., electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, photochemical, thermal or microwave therapy to treat cancer of the prostate.
• •Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc., likely to contribute significant artifact to images).